<DOC>
	<DOCNO>NCT01844947</DOCNO>
	<brief_summary>This study aim analyse tolerability ( side effect safety ) standard treatment ( Javlor® ) addition second anti-tumour drug : sorafenib ( Nexavar® ) . This first time treatment combination study human . Samples blood , urine tumour tissue analyse molecular biomarkers . These biomarkers may potentially help u future predict whether patient benefit cancer treatment . The study also aim investigate new image method , call PET-CT ( positron emission tomography-computed tomography ) , early stage ( normal CT scan ) identify patient benefit give treatment .</brief_summary>
	<brief_title>Phase I Study With Sorafenib Addition Vinflunine Metastatic Transitional Cell Carcinoma Urothelial Tract</brief_title>
	<detailed_description>Objectives - To explore safety sorafenib combination vinflunine patient transitional cell carcinoma urothelial tract define recommend phase II dose treatment combination - To correlate early tracer 18F-FDG-PET/CT functional imaging readout standard RECIST ( version 1.1 ) evaluation intention explore new endpoint target therapy - To find predictive tumour tissue biomarkers sorafenib/vinflunine treatment - To evaluate serum urine marker apoptosis potential marker sorafenib/vinflunine treatment Rationale/Goal To evaluate tolerability activity sorafenib combine vinflunine patient advance metastatic urothelial cancer . Tumour biopsy collect one cycle therapy . The translational part study aim explore predictive value number biomarkers relate targeted property sorafenib presumptive marker vinflunine treatment . In addition , predictive value early functional image tracer 18F-FDG-PET/CT evaluate .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Pelvic Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>sign informed consent ; histologically confirm transitional cell ( pure mixed histology include transitional cell carcinoma allow ) carcinoma urothelial tract ; patient receive neoadjuvant adjuvant platinumcontaining chemotherapy diagnose locoregional recurrent metastatic disease prior 6months‟ visit , eligible patient receive palliative platinumcontaining chemotherapy diagnose progression prior 6months‟ visit , eligible patient contraindication platinumcontaining chemotherapy ; previous systemic chemotherapy must stop 14 day inclusion recovery ( G1 less ) treatment related toxicity ; measurable and/or nonmeasurable disease use RECIST define : Measurable disease : lesion measure least one dimension previously irradiate . Longest diameter 20 mm conventional technique 10 mm spiral CT scan MRI . Nonmeasurable disease : lesion previously irradiate , long diameter &lt; 20 mm conventional technique &lt; 10 mm spiral CT scan MRI , truly non measurable lesion include bone lesion , ascites , pleural/pericardial effusion , lymphangitis cutis/pulmonitis ; age 18 80 year ; ECOG / WHO Performance Status ( PS ) ≤1 ; haematological function : haemoglobin ≥100 g/L absolute neutrophil count 1.0 x LL ( low limit normal value ) platelets 100 x 109/L ; hepatic function : bilirubin &lt; 1.5 x ULN* , transaminases &lt; 2.5 x ULN* *ULN = upper limit normal value renal function : creatinine clearance 40 ml/min ( measure either iohexol clearance CrEDTA technique ) ; Clinically normal cardiac function base ejection fraction ( LVEF assess MUGA ECHO , LVEF ≥50 % ) ; able swallow retain oral medication ; previous treatment related toxicity must grade ≤1 time inclusion presence asthenia , handfoot skin reaction rash grade &gt; 1 ( NCI CTCAE v4.0 ) enrolment ; know suspect allergy investigational agent agent give association trial ; nontransitional cell carcinoma urothelial tract ( e.g . pure adenocarcinoma squamous cell carcinoma ) ; prior treatment vinflunine ; diagnose brain metastasis leptomeningeal involvement . Brain CTscans MRI require unless clinical suspicion central nervous system involvement . peripheral neuropathy G3 ( NCI CTCAE v4.0 ) ; history serious concurrent illness uncontrolled medical disorder ; medical condition might aggravate treatment could control : active infection require antibiotic within 2 week study inclusion , unstable diabetes mellitus , uncontrolled hypercalcaemia &gt; 2.9 mmol/L ( &gt; G2 NCI CTCAE v4.0 ) , concurrent congestive heart failure NYHA ( class IIIIV ) type angina pectoris and/or diagnosis myocardial infarction previous 6 month and/or poorly control hypertension exclude , QTc &gt; 450 m baseline , additional risk factor Torsade de Pointes ( heart failure hypokalemia ( ≥G1 , i.e . PK &lt; LLN2.5 mM ) family history long QTsyndrome ) , cardiac arrhythmia require antiarrhythmic ( exclude betablockers digoxin chronic atrial fibrillation ) ; patient receive one previous systemic chemotherapy advance metastatic disease ; patient receive investigational anticancer therapy 14 day inclusion ; malignancy , except adequately treat basal carcinoma skin insitu cervix carcinoma incidental prostate cancer ( T1a , Gleason score ≤6 , PSA &lt; 0.5 ng/ml ) , tumour disease free survival ≥5 year ; pregnant lactating woman ; men woman childbearing potential employ adequate contraception ; psychological , familial , sociological , geographical condition permit protocol compliance medical followup . poorly control hypertension . At baseline , blood pressure &gt; 150/90 define poorly control . renal dysfunction : creatinine clearance &lt; 40 ml/min measure either iohexol clearance CrEDTA technique . ECOG / WHO Performance Status ≥2 presence handfoot skin reaction rash &gt; G1 enrolment ; know suspect allergy investigational agent agent give association trial ; current medical treatment compound prolongs QTc</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>